Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMingzhao Xiao

About this trial

Bladder cancer (BLCA), with its diverse histopathological features and varying patient outcomes, poses significant challenges in diagnosis and prognosis. Postoperative survival stratification based on radiomics feature and whole slide image feature may be useful for treatment decisions to improve prognosis. In this research, we aim to develop a deep learning-based prognostic-stratification system for automatic prediction of overall and cancer-specific survival in patients with BLCA.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients with bladder cancer who had surgery like radical cystectomy or transurethral resection of bladder tumour (TURBT)

contrast-CT scan less than two weeks before surgery

complete CT image data and clinical data

complete whole slide image data

Disqualifiers

patients with a postoperative diagnosis of non-urothelial carcinoma

poor quality of CT images

incomplete clinical and follow-up data

Trial population

We included patients who had surgery only or who had neoadjuvant chemotherapy before surgery. We excluded patients with a postoperative diagnosis of non-urothelial carcinoma.

Trial design

Design model

Other

Time perspective

Retrospective

Treatments tested in this trial

  • Deep learning system for prognostication prediction in bladder cancer

    Other intervention

    develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images.

Treatment groups

1,000 Participants
are divided into 1 treatment group
Group A: BLCA1 intervention

Trial outcomes

Primary outcomes

1

Overall survival

the time from the date of surgery to death from any cause or the date of last contact (censored observation) at the date of data cut-off.

Time frame
up to 10 years

Secondary outcomes

1

Recurrence free survival

the time from the date of surgery to the date of first documented disease recurrence. Patients without recurrence at the time of analysis will be censored

Time frame
up to 10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mingzhao Xiao

Lead sponsor

First Affiliated Hospital of Chongqing Medical University

Sponsor institution